<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> DOE1-06-0070 </DOCNO><TEXT>Once thought to be the first selective D/sub 1/ dopamine antagonist, theantipsychotic drug SCH23390 now shows evidence of producing its effectby interaction with receptors which may be a subpopulation of the D/sub1/ dopamine receptors. SCH23390 has been tritium labeled in our laboratoryby palladium catalyzed reduction of a brominated precursor with tritiumgas to afford the product with a specific activity of 5.6 Ci/mmole. 10refs. Includes author and subject index.</TEXT></DOC>